DNA Methylation Analysis
Overview
DNA methylation is a key epigenetic mechanism that plays a critical role in gene regulation. Leveraging this cutting-edge science, our DNA Methylation Analysis Technology enables early, accurate, and non-invasive cancer detection. This innovative approach provides unparalleled diagnostic precision, transforming how cancers are identified and managed.
A Strategic Partnership
Our advancements in DNA Methylation Analysis Technology are made possible through a close partnership with EG BioMed, a pioneering leader in cancer diagnostics. This collaboration combines EG BioMed's cutting-edge research and patented methodologies with YD Biopharma’s expertise in clinical applications and market distribution.
Exceptional Accuracy
Sensitivity:
Up to 99% for early-stage cancer detection.
Specificity:
Reduces false positives, ensuring reliable diagnosis.
Cost-Effective and Scalable
Low-cost testing platform based on qPCR ensures affordability without compromising accuracy.
Scalable infrastructure allows for rapid adoption across clinical and research settings.
Streamlined Workflow
User-friendly sample collection and analysis processes minimize complexity for both clinicians and laboratories.
Results are accessible via the EG Biocloud Report System, enabling seamless integration into clinical workflows.
Room Temperature Stability
Samples can be stored and transported at room temperature for up to 14 days, simplifying logistics and reducing costs.
Early Cancer Detection
Progression Monitoring
Identifies cancer-specific DNA methylation patterns, significantly improving patient prognosis.
Effective for cancers that are difficult to detect or monitor, such as pancreatic and breast cancer, where early intervention is critical.
Monitoring Treatment Response
Tracks changes in methylation profiles to evaluate the effectiveness of ongoing treatments.
Supports personalized therapy adjustments based on real-time patient data.
Post-Treatment Surveillance
Detects recurrence risks by monitoring methylation signals, ensuring comprehensive follow-up care.
Offers peace of mind to patients and clinicians by enabling proactive management.
Multi-Cancer Screening
Expands beyond single cancer types to screen for multiple malignancies simultaneously, enhancing diagnostic efficiency.
EG Pancreatic Blood Test Kit
Early-stage pancreatic cancer is notoriously difficult to detect, with an incidence rate nearly matching its mortality rate.
EG Breast Blood Test Kit
Through a simple blood draw, helps breast cancer patients monitor treatment effectiveness and post-surgery follow-ups. Compared to traditional imaging tests, it has a higher potential to detect potential tumor cells earlier.
Product Line
Taiwan
With 10.6% diabetes prevalence, 2.48 million patients, and rising pancreatic cancer risks, Taiwan presents a 10 million-test annual market, creating strong opportunities for strategic partnerships and innovation.
United States
Targeting a potential market of 30 million tests annually with strategic lab partnerships and CAP certification.
Worldwide
Positioned to lead the USD 2.37 billion pancreatic cancer diagnostics market, projected to grow at a 6.53% CAGR by 2030.
Market Potential
YD Biopharma’s Role
Exclusive Commercialization Rights
YD Biopharma is the sole distributor of EG BioMed's DNA Methylation Analysis technology, ensuring global access to these groundbreaking solutions.
Integration into Clinical Practice
We leverage our extensive network and regulatory expertise to bring EG BioMed's innovations to hospitals, clinics, and laboratories worldwide.
Expanding Market Reach
YD Biopharma is focused on expanding access to EG BioMed’s technology. With a strong position in the market, we are poised to align with regulatory trends and growing demand. Our approach ensures global accessibility, enabling hospitals and specialized research facilities to integrate this technology seamlessly.
Cutting-Edge Approach
Our DNA Methylation Analysis technology, powered by cfDNA methylation and qPCR, surpasses traditional methods like CA19-9 and microRNA analysis. Unlike competitors relying on fragile RNA or high-cost NGS platforms, our approach ensures:
Greater stability and repeatability
Faster reporting times
Lower costs, making it accessible to a broader population
